An interventional study of Bone Marrow-Derived PRP and Peripheral Blood-Derived PRP in Epicondylitis, Lateral, sponsored by Clinique du Sport, Bordeaux Mérignac. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-21.
Sponsored by Clinique du Sport, Bordeaux Mérignac · Not applicable, Interventional, and Treatment
Lateral epicondylitis with tendon tear resistant to conservative treatment remains a common clinical condition with limited therapeutic options before surgery is considered.
Platelet-rich plasma (PRP) injections are used in tendinopathies because of their potential regenerative properties. More recently, platelet-rich plasma derived from bone marrow aspirate (bone marrow-derived PRP) has emerged as an alternative source of platelets and bioactive factors. However, the clinical implications of its different biological composition compared with peripheral blood-derived PRP remain poorly understood.
This monocentric randomized pilot trial aims to assess the feasibility of the intervention and to estimate the effect of bone marrow-derived PRP compared with peripheral blood-derived PRP in patients with resistant partial-thickness lateral epicondylar tendinopathy.
Participants will be randomly assigned in a 1:1 ratio to receive either bone marrow-derived PRP or peripheral blood-derived PRP injection. Clinical outcomes, pain, functional scores, imaging findings, safety, and feasibility parameters will be assessed over a 12-month follow-up period.
The study is not powered to demonstrate superiority between treatments but is intended to generate preliminary effect estimates and feasibility data for the design of a future confirmatory trial.
296 studies on the registry are indexed under Tennis Elbow; 64 are open to participants now.
This study's planned enrollment of 24 is below the median of 50 across 262 interventional studies indexed under Tennis Elbow.
Browse Tennis Elbow studies →Clinique du Sport, Bordeaux Mérignac is the lead sponsor of 11 studies on the registry; 11 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive a platelet-rich plasma (PRP) injection prepared from bone marrow aspirate obtained from the posterior iliac crest. After processing, the PRP is injected under ultrasound guidance into the affected lateral elbow tendon.
Procedure: Bone Marrow-Derived PRP
Participants receive a platelet-rich plasma (PRP) injection prepared from peripheral venous blood. After processing, the PRP is injected under ultrasound guidance into the affected lateral elbow tendon.
Procedure: Peripheral Blood-Derived PRP
Participants receive a platelet-rich plasma (PRP) injection prepared from bone marrow aspirate obtained from the posterior iliac crest. After processing, the PRP is injected under ultrasound guidance into the affected lateral elbow tendon.
Participants receive a platelet-rich plasma (PRP) injection prepared from peripheral venous blood. After processing, the PRP is injected under ultrasound guidance into the affected lateral elbow tendon.
Change in QuickDASH score from baseline to 3 months
The primary outcome is the change in the Quick Disabilities of the Arm, Shoulder and Hand (QuickDASH) score between baseline and 3 months. The QuickDASH is a patient-reported questionnaire assessing upper-limb disability and symptoms. Scores range from 0 to 100, with higher scores indicating greater disability.
Time frame: Baseline and 3 months after injection
Change in QuickDASH score at 6 and 12 months
Change in QuickDASH score over time. Scores range from 0 to 100, with higher scores indicating greater disability.
Time frame: Baseline, 6 months, and 12 months after injection
Change in PRTEE score
Change in the Patient-Rated Tennis Elbow Evaluation (PRTEE) score. The PRTEE assesses pain and functional limitations related to lateral elbow tendinopathy. Scores range from 0 to 100, with higher scores indicating worse symptoms and disability.
Time frame: Baseline, 3 months, 6 months, and 12 months after injection
Change in MEPS score
Change in the Mayo Elbow Performance Score (MEPS). The MEPS evaluates pain, range of motion, stability, and function of the elbow. Scores range from 0 to 100, with higher scores indicating better elbow function.
Time frame: Baseline, 3 months, 6 months, and 12 months after injection
Proportion of patients achieving a clinically meaningful improvement
Proportion of participants achieving the minimal clinically important difference (MCID), defined as an improvement of at least 16 points in the QuickDASH score (Scores range from 0 to 100, with higher scores indicating greater disability).
Time frame: 3 months, 6 months, and 12 months after injection
Change in common extensor tendon tear size measured by ultrasound
Change in the size of the common extensor tendon tear measured by ultrasound in longitudinal and transverse planes. Tear size is recorded in millimeters (mm).
Time frame: Baseline, 3 months, 6 months, and 12 months after injection
Rate of surgical treatment during follow-up
Proportion of participants requiring surgical treatment for lateral elbow tendinopathy during the 12-month follow-up period.
Time frame: Up to 12 months after injection
Time to surgery
Time between study inclusion and surgical intervention for lateral elbow tendinopathy.
Time frame: Up to 12 months after injection
Time between study inclusion and surgical intervention for lateral elbow tendinopathy.
Time frame: From injection to 12 months
Participant recruitment rate
Number of participants enrolled divided by the number of eligible participants screened during the recruitment period.
Time frame: Throughout study completion (up to 12 months)
Presence of tendon hypervascularization on ultrasound
Presence or absence of hypervascularization at the common extensor tendon insertion assessed by Doppler ultrasound.
Time frame: Baseline, 3 months, 6 months, and 12 months after injection
Presence of local effusion on ultrasound
Presence or absence of local effusion at the common extensor tendon insertion assessed by ultrasound.
Time frame: Baseline, 3 months, 6 months, and 12 months after injection
Participant retention rate
Proportion of randomized participants who complete the 12-month follow-up.
Time frame: Up to 12 months after injection
Treatment adherence
Proportion of participants who receive the allocated intervention and complete study procedures according to the protocol.
Time frame: From intervention to study completion (12 months)
Completeness of study data collection
Proportion of expected study data collected during follow-up visits.
Time frame: Up to 12 months after injection
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Clinique du Sport, Bordeaux Mérignac